Orbimed Capital, Director: Kinnate Biopharma KNTE Buy · Filed 23/05/02

Trade details

Type: Insider buy
Amount: $1,223,718.16
Shares · price: 467,068 sh · $2.62 a share
Held after: 4,204,852 sh
Stock: Kinnate Biopharma KNTE
Person: Orbimed CapitalDirector
Trade date: 23/05/01
Filed: 23/05/02
Days to filing: 1 days

15 insiders bought this week

Insiders buying this week: 15 insiders
Holding change: +12.5%

Kinnate Biopharma trades, last 26 weeks

What else happened in Kinnate Biopharma around then

Filed or reported within 30 days of the trade day · 23/04/01~23/05/31

Orbimed Capital's recent trades

Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$1.4M
29,385 sh
$1.4M
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$80.3K
1,747 sh
$80.3K
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$433.9K
10,243 sh
$433.9K
Filed 06/15
Traded 06/15
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$7.5M
1,689,189 sh
$7.5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$5M
1,126,126 sh
$5M
Filed 04/23
Traded 04/21